Amedisys Inc (NASDAQ:AMED) will issue its quarterly earnings data after the market closes on Monday, July 31st. Analysts expect the company to announce earnings of $0.50 per share for the quarter.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Tuesday, May 2nd. The health services provider reported $0.47 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.06. The company had revenue of $370.46 million for the quarter, compared to analysts’ expectations of $370.03 million. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. During the same quarter in the previous year, the firm posted $0.33 earnings per share. On average, analysts expect Amedisys to post $2.09 EPS for the current fiscal year and $2.4 EPS for the next fiscal year.

Amedisys Inc (NASDAQ AMED) opened at 59.35 on Monday. The firm’s 50 day moving average price is $61.69 and its 200-day moving average price is $53.66. The firm has a market cap of $2.00 billion, a PE ratio of 43.96 and a beta of 0.94. Amedisys Inc has a 52 week low of $34.58 and a 52 week high of $65.91.

In other news, Director Bruce D. Perkins purchased 500 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was bought at an average cost of $59.69 per share, for a total transaction of $29,845.00. Following the completion of the acquisition, the director now directly owns 13,331 shares of the company’s stock, valued at $795,727.39. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Scott G. Ginn sold 23,828 shares of the company’s stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $58.62, for a total transaction of $1,396,797.36. Following the sale, the insider now owns 13,018 shares of the company’s stock, valued at $763,115.16. The disclosure for this sale can be found here. Insiders have sold 56,828 shares of company stock valued at $3,350,922 over the last 90 days. Corporate insiders own 2.80% of the company’s stock.

Several equities analysts have commented on the stock. Stephens increased their target price on shares of Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 4th. Zacks Investment Research downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, April 18th. BidaskClub downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 12th. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 target price on the stock in a research report on Wednesday, May 3rd. Finally, Royal Bank Of Canada reissued a “hold” rating and set a $56.00 target price on shares of Amedisys in a research report on Monday, June 5th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Amedisys has an average rating of “Buy” and a consensus price target of $58.38.

TRADEMARK VIOLATION NOTICE: “Amedisys Inc (NASDAQ:AMED) Scheduled to Post Quarterly Earnings on Monday” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/24/amedisys-inc-nasdaqamed-scheduled-to-post-quarterly-earnings-on-monday.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Earnings History for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.